ASCO GUIDELINES Bundle

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475484

Contents of this Issue

Navigation

Page 4 of 4

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2022 All rights reserved ASCONEO03224b Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/breast-cancer- guidelines. Copyright © 2022 by American Society of Clinical Oncolog y. All rights reserved. Abbreviations ALND, axillary lymph node dissection; BCS, breast conserving surgery; IBC, inflammatory breast cancer; pCR, pathologic complete response; TNBC, triple negative breast cancer; TIL, tumor infiltrating lymphocyte Source Korde LA, Somerfield MR, Hershman DL, et al. Neoadjuvant Chemotherapy, Endocrine erapy, and Targeted erapy for Breast Cancer Guideline Expert Panel. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022 April 13. doi: 10.1200/JCO.22.00503 Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine erapy, and Targeted erapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485-1505 ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer